Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Self-citationAithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Gotoh, O. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48462-1 · Cited by 1,194
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,134
Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,061
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Maternal and fetal sequelae of anticoagulation during pregnancy
Hall, J. G., Pauli, R. M., & Wilson, K. M. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90181-3 · Cited by 997
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., & Kamali, F. (2005) · Blood · doi:10.1182/blood-2005-03-1108 · Cited by 947
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
Hirsh, J., Fuster, V., Ansell, J., & Halperin, J. L. (2003) · Circulation · doi:10.1161/01.cir.0000063575.17904.4e · Cited by 911
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
Landefeld, C. S., & Beyth, R. J. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90285-w · Cited by 893
Linkins, L.-A., Choi, P. T., & Douketis, J. D. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00007 · Cited by 764
Gage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B. S. P., & Petersen, P. (2004) · Circulation · doi:10.1161/01.cir.0000145172.55640.93 · Cited by 749
Self-citationIdentification of the gene for vitamin K epoxide reductase
Li, T., Chang, C.-Y., Jin, D.-Y., Lin, P.-J., Khvorova, A., & Stafford, D. W. (2004) · Nature · doi:10.1038/nature02254 · Cited by 707
Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study
Fihn, S. D., McDonell, M., Martin, D., Henikoff, J., Vermes, D., Kent, D., White, R. H., & for the Warfarin Optimized Outpatient Follow-up Study Group* (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00005 · Cited by 671
Managing Oral Anticoagulant Therapy
Ansell, J., Hirsh, J., Dalen, J., Bussey, H., Anderson, D., Poller, L., Jacobson, A., Deykin, D., & Matchar, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.22s · Cited by 572
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 468
Taube, J., Halsall, D., & Baglin, T. (2000) · Blood · doi:10.1182/blood.v96.5.1816 · Cited by 392
Sanderson, S., Emery, J., & Higgins, J. (2005) · Genetics in Medicine · doi:10.1097/01.gim.0000153664.65759.cf · Cited by 363
Beyth, R. J., Quinn, L., & Landefeld, C. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-9-200011070-00010 · Cited by 360
Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy
Harrison, L., Johnston, M., Massicotte, M. P., Crowther, M., Moffat, K., & Hirsh, J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-2-199701150-00006 · Cited by 359
Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Steward, D. J., Haining, R. L., Henne, K. R., Davis, G., Rushmore, T. H., Trager, W. F., & Rettie, A. E. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00004 · Cited by 303
Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., & Ginsberg, J. S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3431 · Cited by 269
Interindividual variability in sensitivity to warfarin-Nature or nurture?
Loebstein, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117444 · Cited by 260
Majeed, A., Moser, K., & Carroll, K. (2001) · Heart · doi:10.1136/heart.86.3.284 · Cited by 253
Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin
Kidd, R. S., Curry, T. B., Gallagher, S., Edeki, T., Blaisdell, J., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00008 · Cited by 236
Gage, B. F., Birman-Deych, E., Radford, M. J., Nilasena, D. S., & Binder, E. F. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.2.241 · Cited by 233
Self-citationGenetic Modulation of Oral Anticoagulation with Warfarin
Colaizzo, D., D’Andrea, G., Brancaccio, V., Ciampa, A., Grandone, E., Di Minno, G., & Margaglione, M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614114 · Cited by 233
Aging and the Anticoagulant Response to Warfarin Therapy
Gurwitz, J. H., Avorn, J., Ross-Degnan, D., Choodnovskiy, I., & Ansell, J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-11-901 · Cited by 231
Major bleeding after hospitalization for deep-venous thrombosis
White, R. H., Beyth, R. J., Zhou, H., & Romano, P. S. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00267-3 · Cited by 198
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
Wadelius, M., Sörlin, K., Wallerman, O., Karlsson, J., Yue, Q.-Y., Magnusson, P. K. E., Wadelius, C., & Melhus, H. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500220 · Cited by 191
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
Voora, D., Eby, C., Linder, M. W., Milligan, P. E., Bukaveckas, B. L., McLeod, H. L., Maloney, W., Clohisy, J., Burnett, S. R., Grosso, L., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0542 · Cited by 189
Self-citationRisk factors for complications of chronic anticoagulation
Patton, P. J. (1994) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(94)90043-4 · Cited by 189
Genetic-based dosing in orthopedic patients beginning warfarin therapy
Millican, E. A., Lenzini, P. A., Milligan, P. E., Grosso, L., Eby, C., Deych, E., Grice, G., Clohisy, J. C., Barrack, R. L., Burnett, R. S. J., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069609 · Cited by 178
Self-citationA coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance
Loebstein, R., Dvoskin, I., Halkin, H., Vecsler, M., Lubetsky, A., Rechavi, G., Amariglio, N., Cohen, Y., Ken-Dror, G., Almog, S., et al. (2007) · Blood · doi:10.1182/blood-2006-08-038984 · Cited by 171
Takahashi, H., Kashima, T., Nomoto, S., Iwade, K., Tainaka, H., Shimizu, T., Nomizo, Y., Muramoto, N., Kimura, S., & Echizen, H. (1998) · Pharmacogenetics · doi:10.1097/00008571-199810000-00001 · Cited by 162
Shikata, E., Ieiri, I., Ishiguro, S., Aono, H., Inoue, K., Koide, T., Ohgi, S., & Otsubo, K. (2004) · Blood · doi:10.1182/blood-2003-09-3043 · Cited by 159
Visser, L. E., van Vliet, M., van Schaik, R. H., Kasbergen, A. A. H., Smet, P. A. G. M. D., Vulto, A. G., Albert Hofman, D., van Duijn, C. M., & Stricker, B. H. C. (2003) · Pharmacogenetics · doi:10.1097/00008571-200401000-00003 · Cited by 112
A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.
Chu, K. C., Wu, S. M., Stanley, T. E., Stafford, D. W., & High, K. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118956 · Cited by 106
Oldenburg, J., Quenzel, E., Harbrecht, U., Fregin, A., Kreß, W., Müller, C. R., Hertfelder, H.-J., Schwaab, R., Brackmann, H., & Hanfland, P. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2213036.x · Cited by 96
Osman, A., Enström, C., Arbring, K., Söderkvist, P., & Lindahl, T. L. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02039.x · Cited by 57
Roberts, G. W., Druskeit, T., Jørgensen, L. E., Wing, L. M. H., Gallus, A. S., Miller, C., Cosh, D. G., & Eaton, V. S. (1999) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1999.tb01623.x · Cited by 56
Anderson, C. A. M., Jørgensen, A. L., Deeb, S. S., McLerran, D., Beresford, S. A. A., & Motulsky, A. G. (2005) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30391 · Cited by 48
Sugiyama, T., Takaki, T., Sakanaka, K., Sadamaru, H., Mori, K., Kato, Y., Taguchi, T., & Saito, T. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0119 · Cited by 48
Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring
Ezekowitz, M. D., James, K. E., Radford, M. J., Rickles, F. R., & Redmond, N. (1999) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849900400102 · Cited by 29
Cited by
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.185 · Cited by 647
Self-citationThe largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134247 · Cited by 481
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464
Metadata
- Authors
- Gage, B. F., & Lesko, L. J.
- Venue
- Journal of Thrombosis and Thrombolysis
- Published
- 2007-10-01
- Volume
- 25
- Issue
- 1
- Pages
- 45-51
- ISSN
- 0929-5305 (ISSN-L)
- 1573-742X
- OpenAlex
- W2148232829
- Cited by
- 254
- References
- 45
- FWCI
- 22.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.